Tumor necrosis factor and Interleukin-1 beta (TNF-alpha and IL-1 beta)

Tumor necrosis factor (TNF) and Interleukin-1 beta (IL-1 beta) are critical pro-inflammatory cytokines that function as primary mediators of the innate immune response and systemic inflammation (UniProt P01375, P01584). Tumor necrosis factor is a pleiotropic cytokine involved in a wide range of biological processes, including cell proliferation, differentiation, and apoptosis, and is a key driver of the acute phase response (PubMed: 26361060). Interleukin-1 beta is produced as an inactive precursor that requires processing by the inflammasome-activated enzyme caspase-1 to become biologically active, subsequently inducing fever and the expression of other inflammatory mediators (StatPearls: NBK470204). Dysregulation and overproduction of these cytokines are central to the pathogenesis of numerous chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and various autoinflammatory syndromes (PubMed: 12758023). Therapeutic strategies targeting these molecules include monoclonal antibodies and soluble decoy receptors designed to neutralize the cytokines before they can activate their respective signaling pathways (PubChem: CID 135315435). While these therapies have revolutionized the treatment of inflammatory diseases, they are associated with significant safety risks, including an increased susceptibility to serious opportunistic infections and potential long-term risks of malignancy (NIH: PMC3135440).

Other names

TNFTNFACachectinTumor necrosis factor-alphaIL1BIL-1BCatabolinInterleukin-1 beta

Neutralization of pro-inflammatory cytokines to prevent their binding to cell-surface receptors, thereby inhibiting downstream signaling pathways such as NF-kappaB and MAPK that drive inflammation and tissue destruction.